Switch to: References

Add citations

You must login to add citations.
  1. Innovative therapies, suspended trials, and the economics of clinical research: Facilitated communication and biomedical cases.James R. Wible & Susan Dietrich - 2002 - Philosophy of the Social Sciences 32 (3):275-309.
    University of North Carolina at Greensboro Most approaches to the philosophy of the natural and social sciences are basedon completed scientific investigations. However, there are many importantcases in science in which testing is incomplete. These cases are termed suspendedtrials and are particularly significant in biomedical and allied health fields. Initially,the authors' interest in suspended trials was piqued by a controversialmethod for assisting autistic children known as facilitated communication. Thisarticle examines facilitated communication and other examples of suspendedtrials from the perspective of (...)
    Direct download  
     
    Export citation  
     
    Bookmark  
  • A framework for risk-benefit evaluations in biomedical research.Annette Rid & David Wendler - 2011 - Kennedy Institute of Ethics Journal 21 (2):141-179.
    One of the key ethical requirements for biomedical research is that it have an acceptable risk-benefit profile (Emanuel, Wendler, and Grady 2000). The International Conference of Harmonization guidelines mandate that clinical trials should be initiated and continued only if “the anticipated benefits justify the risks” (1996). Guidelines from the Council for International Organizations of Medical Sciences state that biomedical research is acceptable only if the “potential benefits and risks are reasonably balanced” (2002). U.S. federal regulations require that the “risks to (...)
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark   29 citations  
  • Regulating Research and Experimentation: A View from the UK.Sheila A. M. McLean - 2004 - Journal of Law, Medicine and Ethics 32 (4):604-612.
    A medical profession which did not seek improved means to conquer disease would be condemned for dereliction of its duty, Members of the public will not accept the current state of the medical arts as finite but feel justified in expecting the development of more effective therapies for illness, and the promotion of improved means of preventive care.With this assertion, the distinguished academic, Bernard Dickens, places research firmly in the domain of the public interest. Foster agrees, saying that, “[t]o improve (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  • Regulating Research and Experimentation: A View from the UK.Sheila A. M. McLean - 2004 - Journal of Law, Medicine and Ethics 32 (4):604-612.
    A medical profession which did not seek improved means to conquer disease would be condemned for dereliction of its duty, Members of the public will not accept the current state of the medical arts as finite but feel justified in expecting the development of more effective therapies for illness, and the promotion of improved means of preventive care.With this assertion, the distinguished academic, Bernard Dickens, places research firmly in the domain of the public interest. Foster agrees, saying that, “[t]o improve (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  • Regulating Research and Experimentation: A View from the UK.Sheila Mc Lean - 2004 - Journal of Law, Medicine and Ethics 32 (4):604-612.
    A medical profession which did not seek improved means to conquer disease would be condemned for dereliction of its duty, Members of the public will not accept the current state of the medical arts as finite but feel justified in expecting the development of more effective therapies for illness, and the promotion of improved means of preventive care.With this assertion, the distinguished academic, Bernard Dickens, places research firmly in the domain of the public interest. Foster agrees, saying that, “[t]o improve (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
    		•
  • Defining and Describing Benefit Appropriately in Clinical Trials.Nancy M. P. King - 2000 - Journal of Law, Medicine and Ethics 28 (4):332-343.
    Institutional review boards and investigators are used to talking about risks of harm. Both low risks of great harm and high risks of small harm must be disclosed to prospective subjects and should be explained and categorized in ways that help potential subjects to understand and weigh them appropriately. Everyone on an IRB has probably spent time at meetings arguing over whether a three-page bulleted list of risk description is helpful or overkill for prospective subjects. Yet only a small fraction (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   66 citations